The new drugs this company is developing could be worth a lot more than the present market value of its stock. Shares of Viking Therapeutics (VKTX 0.43%), a clinical-stage drugmaker working on metabolic treatments, have tripled in value this year. Despite the huge run-up, analysts who follow the company think it has heaps more upside. The average analyst who follows Viking Therapeutics thinks it can rise to $113.55 per share. Reaching the consensus expectation would result in a gain of about 76% from the st ...